Oxford Nanopore has continued its funding streak with another $108m, bringing this year's haul to more than $208m and its overall total to around $800m.

The Amgen and Illumina-backed genetic sequencing equipment provider brought its funding this year to more than $206m and its overall total to about $800m.

GV, Orient Life and Illumina Ventures are in line to exit cell therapy and vaccine developer SQZ Biotechnologies, which has filed for a $75m offering.

Existing investor Lilly Asia Ventures helped the genome editing technology developer push its overall funding past the $100m mark.

The Omron-backed disease prevention platform developer hiked its total debt and equity financing to $100m, King River Capital leading the series C.

The multicorporate-backed corporate venturing vehicle for online food wholesaler Oisix Ra Daichi has secured chemicals producer Fuso as an LP.

MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Tigermed took part in a round that will support clinical progression of a 3D Medicines product pipeline that includes oncology candidate envafolimab.